ArticleBritish journal of cancer2013

Reply: Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?

D J Rosario et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.